Stoke Therapeutics (STOK) Gains from Investment Securities (2018 - 2026)

Stoke Therapeutics' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 31.54% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 31.54% YoY), while the FY2025 annual figure was $868987.0, down 89.13% from the prior year.
• Gains from Investment Securities was $1.3 million for Q1 2026 at Stoke Therapeutics, down from $12.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $12.0 million in Q4 2025 to a low of $79400.0 in Q3 2022.
• Historically, Gains from Investment Securities has averaged $2.2 million across 5 years, with a median of $998356.0 in 2024.
• Biggest YoY gain for Gains from Investment Securities was 7210.26% in 2022; the steepest drop was 93.65% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at $3.5 million in 2022, then sank by 97.22% to $96340.0 in 2023, then surged by 8197.96% to $8.0 million in 2024, then jumped by 50.01% to $12.0 million in 2025, then plunged by 88.82% to $1.3 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.3 million (Q1 2026), $12.0 million (Q4 2025), and $809300.0 (Q3 2025), per Business Quant data.